Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.44 |
| ▸ | KMO | O15229 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL727056 | 1.00 | TSHR (0.57) | TSHRSRD5A2ALOX5HSD11B1KMO | |
| SCHEMBL726538 | 1.00 | TSHR (0.57) | TSHRSRD5A2ALOX5HSD11B1KMO | |
| SCHEMBL728234 | 0.82 | TSHR (0.53) | TSHRSRD5A2ALOX5KMOMEN1 | |
| SCHEMBL726466 | 0.82 | TSHR (0.53) | TSHRSRD5A2ALOX5KMOMEN1 | |
| SCHEMBL8097035 | 0.82 | TSHR (0.49) | TSHRSRD5A2ALOX5KDM4EMEN1 | |
| SCHEMBL727067 | 0.82 | TSHR (0.49) | TSHRSRD5A2ALOX5KDM4EMEN1 | |
| SCHEMBL9193565 | 0.81 | TSHR (0.55) | TSHRSRD5A2ALOX5KMOKDM4E | |
| SCHEMBL728333 | 0.80 | KMT2A (0.47) | KDM4EMEN1NPC1MAPTPKM | |
| SCHEMBL8089458 | 0.79 | ALOX15 (0.52) | TSHRSRD5A2MEN1MAPTKMT2A | |
| SCHEMBL3678941 | 0.79 | ALOX15 (0.52) | TSHRSRD5A2MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4813800-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | claimed |
| EP-1581215-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| EP-1581216-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004060368-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| WO-2004060369-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| US-7727977-B2 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | MERCK PATENT GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| EP-1581215-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| EP-1581216-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | disclosed |
| WO-2004060368-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES BY INCREASING THE NUMBER OF ISLETS OF LANGERHANS CELLS | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060369-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | disclosed |
| US-6048896-A | FOR TREATMENT OF BRAIN OR NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-04-11 | — | — | US | disclosed |
| EP-0858442-A1 | 4-PHENYL-4-OXO-2-BUTENOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997017316-A1 | 4-PHENYL-4-OXO-2-BUTENOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | KYNU, KMO, IDO1 | TSHR 2567/4885SRD5A2 886/4885ALOX5 102/4885 |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | KYNU, KMO, AADAT | TSHR 2294/4885SRD5A2 416/4885ALOX5 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.